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Abstract The effect of hepatocyte growth factor/scatter factor
(HGF/SF) during wound healing in the skin was investigated,
using HGF/SF-overexpressing transgenic mouse model. Histo-
logical analysis of HGF/SF transgenic mouse excisional wound
sites revealed increased granulation tissue with marked vascular-
ization. Northern blot analysis demonstrated that, relative to
control, vascular endothelial growth factor (VEGF) expression in
transgenic skin was significantly higher at baseline and was
robustly up-regulated during wound healing. Elevated levels of
VEGF protein were detected immunohistochemically, predomi-
nantly in endothelial cells and fibroblasts within the granulation
tissue of HGF/SF transgenic skin. Serum levels of VEGF were
also elevated in HGF/SF transgenic mice. Thus, results from our
study suggest that HGF/SF has a significant effect on
vascularization and granulation tissue formation during wound
healing in vivo, involving with induction of VEGF. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
Key words: Hepatocyte growth factor/scatter factor;
Vascular endothelial growth factor; Wound healing;
Angiogenesis; Transgenic mouse
1. Introduction
The process of cutaneous wound healing is characterized by
four overlapping repair phases involving hemostasis, in£am-
mation, proliferation, and remodeling. After injury, new tissue
formation starts with re-epithelialization and is followed by
granulation tissue formation. The latter process encompasses
macrophage accumulation, ¢broblast ingrowth, matrix depo-
sition and angiogenesis [1]. Angiogenesis, the formation of
new blood vessels from existing blood vessels, is an essential
step during wound healing and is driven in part by a complex
mixture of growth factors and cytokines, which are released
into the area of injury. New vessels are necessary for supply-
ing nutrients and oxygen to the cells involved in the repair
process, for removal of debris and formation of granulation
tissue. Of a number of cytokines involved in the wound heal-
ing process, vascular endothelial growth factor (VEGF), basic
¢broblast growth factor (bFGF), and transforming growth
factor (TGF) K have been detected in wound transudate
and reported to contribute to the angiogenic response after
injury [2^4].
Hepatocyte growth factor/scatter factor (HGF/SF) was ¢rst
recognized as a highly potent hepatocyte mitogen [5,6] ; how-
ever, it is now known to be a pleiotropic cytokine that helps
regulate cell growth, movement, morphogenesis, development,
and regeneration of various tissues [7^11]. Its receptor has
been identi¢ed as the c-Met proto-oncogene product, a trans-
membrane tyrosine kinase that is expressed on the surface of
epithelial cells [8,12]. HGF/SF is produced mainly by mesen-
chymal cells such as ¢broblasts and smooth muscle cells [13^
15] and is considered to play an important role in mesenchy-
mal-epithelial/endothelial interactions that contribute to em-
bryogenesis, organ regeneration, wound healing, and angio-
genesis [16^19].
Previous investigations have established that HGF/SF di-
rectly stimulates proliferation and migration of cultured en-
dothelial cells, promotes development of capillary-like struc-
tures in vitro, and stimulates blood vessel formation in
Matrigel plugs and in the cornea [19^22]. More recently,
HGF/SF has been shown to produce an angiogenic e¡ect
via induction of VEGF in vitro [23,24]. Although it is known
that HGF/SF in£uences the growth of endothelial cells and
keratinocytes [23^25], the precise in vivo e¡ects of HGF/SF
during skin wound healing are still poorly understood. In this
study, we investigated the in vivo e¡ects of HGF/SF on the
process of wound healing using the HGF/SF-overexpressing
transgenic mice as a model system.
2. Materials and methods
2.1. Animals
Transgenic mice overexpressing a mouse HGF/SF cDNA by means
of the mouse metallothionein gene promoter were generated on an
FVB/N background as described previously [26]. All animal studies
were performed according to the guidelines for animal care and use
established by Gunma University School of Medicine.
2.2. In vivo wound assay
Animals were anesthetized by inhalation of diethyl ether, and the
dorsal hair was removed using a hair remover (Hair Remover, Na-
tional, Osaka, Japan). Full-thickness dermal wounds (6 mm diameter)
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were made on the dorsum of 7-week-old female mice with a standard
biopsy punch (Maruho, Osaka). At selected time intervals, mice were
sacri¢ced and wounds were harvested with a rim of approximately
2 mm of unwounded tissue, ¢xed in 10% bu¡ered formalin, embedded
in para⁄n, and stained with hematoxylin and eosin (HpE).
2.3. Immunohistochemistry
For immunohistochemical analysis of VEGF, formalin-¢xed and
para⁄n-embedded wounds were sectioned at a thickness of 10 WM.
An anti-mouse VEGF monoclonal antibody (Santa Cruz Biotechnol-
ogy, CA, USA) was used at a concentration of 2 Wg/ml at room
temperature for 1 h. After rinsing, slides were incubated with the
secondary goat anti-mouse antibody for 1 h at room temperature.
Slides were then rinsed and incubated with an avidin^biotin^peroxi-
dase complex (Vectastain ABC kit, Burlingame, CA, USA) followed
by 3,3P-diamino-benzidine tetrahydrochloride (Wako, Tokyo, Japan)
color development. The distribution of HGF/SF protein was analyzed
as described above except that anti-human HGF/SF monoclonal anti-
body (RpD systems, Minneapolis, MO, USA) was used at a concen-
tration of 50 Wg/ml at room temperature for 15 h and then slides were
incubated with the secondary goat anti-mouse antibody. Immunoloc-
alization of platelet endothelial cell adhesion molecule-1 (PECAM-1)
was performed as described above except that frozen embedded sec-
tions were ¢xed in acetone for 5 min, and sections were incubated
with secondary rat anti-mouse antibody. The antibody (clone MEC
13.3, Pharmingen, San Diego, CA, USA) was applied at a concentra-
tion of 10 Wg/ml.
2.4. Northern blot analysis
Wounds from mice at di¡erent time points were excised and frozen
immediately in liquid nitrogen. For each time point, six wounds were
pooled and total RNA was prepared using TRIZOL reagent (Gibco
BRL, Grand Island, NY, USA) following the instructions provided by
the manufacturer. For Northern blot hybridization, 20 Wg of total
RNA were loaded per lane onto an agarose gel, electrophoresed
and then transferred to nylon membrane. HGF/SF and c-Met tran-
scripts were detected with a 32P-labeled mouse cDNA probe generated
by polymerase chain reaction (PCR) as described previously [26,27].
VEGF transcripts were detected with a 32P-labeled human VEGF
cDNA probe generated by PCR using the clone LA737 (kindly pro-
vided by Dr. W.J. LaRochelle) as a template, and the following set of
primers: 5P-GTAAAACGACGGCCAGT-3P and 5P-CAGGAAACA-
GCTATGAC-3P. To control for RNA loading and transfer variation,
¢lters were routinely rehybridized with a glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe.
2.5. Quanti¢cation of wound healing
The number of blood vessels was analyzed under a microscope by
counting PECAM-1-positive ¢gures within granulation tissue (area
per high power ¢eld (HPF)). Estimation of neodermal formation
was performed on Azan Mallory-stained sections. Using a standard
ocular grid, the thickness of the intact dermis and thickness of the
dermis at the center of the wound site were measured. The percentage
of neodermal formation was estimated by the following formula: %
neodermal formation = (thickness of dermis at the center of the
wound/thickness of intact dermis) U100, as modi¢ed by Swift et al.
[28].
2.6. Determination of VEGF levels in serum
Blood samples were collected and serum was separated by centri-
fugation, immediately frozen, and stored at 380‡C. Serum was col-
lected from ¢ve animals per time point for each genotype. Serum
VEGF levels were determined using a mouse VEGF enzyme-linked
immunosorbent assay (ELISA) kit (RpD Systems) according to the
method recommended by the manufacturer.
2.7. Statistical analysis
The results are expressed as mean þ S.D. Statistical analysis was
performed by repeated measure analysis of variance and subsequent
Fisher’s PLSD test. P6 0.05 was considered statistically signi¢cant.
3. Results
3.1. HGF/SF transgene expression in the skin
Northern blot analysis showed that the 2.4 kb HGF/SF
transgenic transcript was strongly expressed in the skin of
transgenic mice (Fig. 1). When the c-Met receptor mRNA
level was analyzed by Northern blot hybridization, no signi¢-
cant di¡erence in amount of c-Met transcript was detected
between HGF/SF transgenic and FVB/N control mice.
3.2. Histological appearance of healing wounds
Microscopic examination revealed that regenerating granu-
lation tissue from the HGF/SF transgenic mice exhibited more
prominent vascularity and a highly accelerated granulation
tissue formation relative to control mice. These two dramatic
changes became apparent from day 3 and were obvious at day
21 of the observation period. In HpE-stained sections, HGF/
SF transgenic mouse wounds demonstrated more robust der-
mal blood vessel formation, around which dense and thick
mesenchymal matrix deposition was observed (Fig. 2B, D
versus Fig. 2A, C). Examination of Azan Mallory-stained
wound sections revealed dense and thick stromal tissue for-
mation in HGF/SF transgenic mice (Fig. 2F) compared with
non-transgenic littermates (Fig. 2E).
To further quantify this overt increase in blood vessels,
immunohistological analysis of endothelial cells was carried
out using anti-PECAM-1 antibodies. Fig. 2H shows a marked
increase in the number of blood vessels in the regenerating
transgenic skin compared with wild type (Fig. 2G). No sig-
ni¢cant di¡erences were observed in capillary content prior to
wounding. However, a prominent number of red blood cells
were observed in granulation tissue of HGF/SF transgenic
mice commencing at day 3, accompanied by the formation
of new blood vessels. Quanti¢cation of blood vessels demon-
strated a prolonged period of neovascularization in HGF/SF
transgenic mice (Fig. 3A). On day 14, the number of blood
vessels in granulation tissue of HGF/SF transgenic mice
(45.3 þ 7.9 per HPF) was signi¢cantly increased compared
with control mice (27.6 þ 1.7 per HPF) (P6 0.01). Unlike con-
trol wounds, in which a decrease in vascularization occurred
with time, HGF/SF transgenic mouse wounds remained
highly vascularized throughout the observation period
(61.8 þ 10.7 and 13.5 þ 1.9 per HPF on day 21, in HGF/SF
transgenic and control mice, respectively) (P6 0.01).
We also quanti¢ed the e¡ect of HGF/SF overexpression on
granulation tissue formation in our wound model (Fig. 3B).
The rate of neodermal formation was calculated using the
formula described in Section 2. Neodermal formation of
Fig. 1. Analysis of transgenic HGF/SF and endogenous c-Met tran-
scripts in transgenic mouse skin by Northern blot hybridization.
HGF/SF transgene expression and endogenous c-Met expression in
skin from 7-week-old control (C) and transgenic mice (Tg) before
wound induction. Transgenic HGF (Tg HGF) was strongly ex-
pressed in the skin of transgenic mice. No signi¢cant di¡erence in
the amount of c-Met transcripts was detected between HGF/SF
transgenic and FVB/N control mice. Filters were rehybridized with
a GAPDH probe to assess RNA loading and transfer variation.
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non-transgenic mice was calculated to be an average of 12.8%
on day 3, 36.6% on day 7 and 56.7% on day 14. In contrast,
neodermal formation in the HGF/SF transgenic mice pro-
ceeded much more rapidly with an average of 15.3, 75.2 and
97.4% on days 3, 7 and 14, respectively. Even at day 21,
wounds in non-transgenic mice had not completely recovered
(approximately 80% of neodermal formation).
3.3. VEGF mRNA expression associated with HGF/SF during
wound healing
In order to determine whether the observed HGF/SF-medi-
ated angiogenesis detected during wound healing was associ-
ated with VEGF induction, VEGF mRNA levels before
and after injury were analyzed by Northern blot hybridiza-
tion (Fig. 4A). Previously, VEGF mRNA transcripts of
various sizes (2.7V4.2 kb) have been reported in a number
of mouse tissues [29]. In the present study, a 4.2 kb transcript
was observed in both HGF/SF transgenic and non-transgenic
mice, and an additional 3.7 kb transcript was observed only
in the HGF/SF transgenic mice. In both genotypes, the
level of 4.2 kb transcript reached a peak value on day 7,
however, it was more strongly up-regulated in HGF/SF trans-
genic mice than in non-transgenic mice. In HGF/SF transgen-
ic mice, the 3.7 kb transcript was observed before injury,
Fig. 2. Histological features during wound healing in the skin of control and HGF/SF transgenic mice (day 21). Low power view of wound
sites from control (A) and HGF/SF transgenic (B) mice. Note the markedly thickened granulation tissue in the transgenic wound site (B). C
and D: High power views of granulation tissue from the same animals shown in (A) and (B), respectively. The presence of markedly increased
and highly vascularized granulation tissue was observed in transgenic mice. E and F: Azan Mallory-stained sections demonstrate greater depo-
sition of collagen ¢bers in the HGF/SF transgenic mouse wounds (F) than in control wounds (E). G and H: PECAM-1 staining demonstrated
a marked increased number of blood vessels in the granulation tissue of transgenic skin (H) than in controls (G). A^D: HpE; E and F: Azan
Mallory; G and H: anti-PECAM-1 antibody. Original magni¢cations: A and B, U40; C and D, U200; E and F, U10; G and H, U100.
FEBS 25515 26-11-01 Cyaan Magenta Geel Zwart
M. Toyoda et al./FEBS Letters 509 (2001) 95^100 97
reached a peak level on day 3, and then decreased towards
day 14.
3.4. Serum levels of VEGF during wound healing
Serum VEGF levels were measured on days 0, 7, and 14
after wound induction (Fig. 4B). Prior to injury, serum levels
of VEGF in HGF/SF transgenic mice (68.1 þ 10.3 pg/ml,
range 60.2^85.3 pg/ml) were already higher than those in their
non-transgenic littermates (32.1 þ 9.17 pg/ml, range 18.9^42.9
pg/ml) (P6 0.01). At day 7, serum VEGF levels in HGF/SF
transgenic mice (104.3 þ 11.4 pg/ml, range 91.1^115.6 pg/ml)
were signi¢cantly elevated compared with those at baseline
(P6 0.01), while VEGF levels of non-transgenic littermates
(41.6 þ 6.90 pg/ml, range 32.3^48.2 pg/ml) exhibited no signi¢-
cant changes. In HGF/SF transgenic mice, serum VEGF lev-
els declined to baseline by day 14.
3.5. Immunolocalization of HGF/SF and VEGF during wound
healing
Immunohistological analysis at day 14 revealed that HGF/
SF protein was detected mainly in endothelial cells and ¢bro-
blasts within the granulation tissue at a higher level in trans-
genic mice relative to controls (Fig. 5A versus B). The expres-
sion level of VEGF was a¡ected by overexpression of HGF/
SF; ¢broblasts and endothelial cells in the granulation tissue
expressed much higher levels of VEGF in HGF/SF transgenic
mice than in non-transgenic littermates (Fig. 5C versus D).
4. Discussion
The results of the present study demonstrate that overex-
pression of HGF/SF accelerates neovascularization as well as
granulation tissue formation during wound healing. This is
the ¢rst report, to the best of our knowledge, in which
HGF/SF has been shown to promote angiogenesis involving
with induction of VEGF in vivo.
The e¡ect of growth factors on wound healing has been
investigated both through administration of growth factors
and by analyzing transgenic animals. TGFK, bFGF, epider-
mal growth factor, and keratinocyte growth factor have all
been shown to promote epithelial regeneration and dermal
tissue formation [30^34]. Quaglino et al. reported that
TGFL1 enhanced granulation tissue formation but not regen-
Fig. 3. A: Quanti¢cation of blood vessels on days 0, 14 and 21. At
day 14, the number of blood vessels in granulation tissue from
HGF/SF transgenic mice was signi¢cantly higher than in control
mice (P6 0.01), and remained high on day 21 (P6 0.01). Six
wounds per time point for each genotype were quantitated (area per
HPF). B: Promotion of granulation tissue formation by HGF/SF
overexpression. The rate of neodermal formation was calculated us-
ing the formula described in Section 2. Neodermal formation oc-
curred much more rapidly in HGF/SF transgenic mice than in con-
trol mice. a : control mice, b : HGF/SF transgenic mice. Six
wounds per time point for each genotype were quantitated.
Fig. 4. A: Northern blot analysis of VEGF transcripts in mouse
skin during wound healing. Transcripts of approximately 4.2 kb
were observed in both HGF/SF mice and non-transgenic mice, while
an additional transcript of 3.7 kb was observed only in HGF/SF
transgenic mouse skin. In both genotypes, the 4.2 kb transcript
peaked on day 7; however, it was more strongly up-regulated in
HGF/SF transgenic mice than in controls. In HGF/SF transgenic
mice, the 3.7 kb transcript was observed prior to injury, peaked on
day 3, and then declined towards day 14. B: Serum levels of VEGF
during wound healing. Serum VEGF levels were measured at days
0, 7 and 14. Prior to wound induction, serum VEGF in HGF/SF
transgenic mice was already higher than in non-transgenic litter-
mates (P6 0.01). At day 7, serum VEGF in HGF/SF transgenic
mice was signi¢cantly elevated relative to baseline (P6 0.01), while
non-transgenic littermates exhibited no signi¢cant changes. a : con-
trol mice, b : HGF/SF transgenic mice. Five samples per time point
for each genotype were analyzed.
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eration of the epithelia [35]. With respect to angiogenesis, an
essential process of wound healing, VEGF, bFGF, and TGFK
have been reported to have a potent angiogenic e¡ect after
injury [2^4]. VEGF, originally puri¢ed on the basis of its
vascular permeability-enhancing activity [36], is a powerful
vascular endothelial cell-speci¢c mitogen [37,38] and acts as
a mediator of both physiologic and pathologic angiogenesis
[39^41]. On the other hand, HGF/SF, which was ¢rst recog-
nized as a highly potent hepatocyte mitogen [5,6], has been
identi¢ed as an angiogenic growth factor [19^22]. Recent stud-
ies have shown that HGF/SF is capable of inducing VEGF in
cultured keratinocytes and endothelial cells [23,24]. Moreover,
Belle et al. demonstrated that the combination of HGF/SF
and VEGF produced an additive e¡ect on proliferation of
endothelial cells and a synergistic e¡ect on endothelial migra-
tion [23]. HGF/SF thus may a¡ect the biological behavior of
endothelial cells through a combination of the direct e¡ects of
HGF/SF itself and indirect e¡ects mediated via induction of
VEGF in vitro. The observed up-regulation of VEGF in our
HGF/SF-overexpressing wound model is consistent with re-
cent in vitro studies. Since HGF/SF-dependent up-regulation
of VEGF was observed at the level of both mRNA and pro-
tein, it is probable that angiogenesis in this transgenic wound
healing model was due in part to VEGF induction through
HGF/SF overexpression.
Although the level of VEGF expression in HGF/SF trans-
genic mice was already higher than in controls prior to wound
induction, no overt phenotype concerning vascular bed was
noted in the skin as well as other organs. Alternatively, it has
been shown that intra-arterial or intra-muscular administra-
tion of VEGF may signi¢cantly augment perfusion and devel-
opment of collateral vessels in a rabbit model where chronic
hindlimb ischemia was created by surgical removal of the
femoral artery [42]. However, the exact in vivo e¡ect of ad-
ministration of VEGF in the absence of tissue damage is not
clear. It is possible that VEGF associated with HGF/SF over-
expression only stimulates angiogenesis under speci¢c patho-
logic conditions, such as tissue injury or hypoxia resulting
from arterial occlusion. To date, several reports have demon-
strated induction of VEGF by HGF/SF in various cell types,
such as keratinocytes, endothelial cells, and glioma cells that
express the c-Met receptor [23,24,43]. In this point Dong et al.
reported that HGF/SF induces expression of VEGF through
both MEK- and PI3K-dependent pathways [44].
We also demonstrated that overexpression of HGF/SF af-
fected the generation of granulation tissue. A previous study
demonstrated that HGF/SF enhanced wound closure by in-
£uencing the migratory and spreading response in cultured
intestinal epithelial cells [45]. Based on the duration of wound
scab formation and microscopic examination, HGF/SF over-
expression did not overtly a¡ect wound closure in the present
study. However, neodermal formation was highly promoted,
as judged by enhanced proliferation of endothelial cells and
¢broblasts in HGF/SF transgenic mice. We suggest that pro-
liferation of endothelial cells in transgenic mice may be due to
the combined e¡ect of HGF/SF itself and HGF/SF-induced
VEGF. Since ¢broblasts do not express c-Met, enhanced ¢-
broblast proliferation in transgenic granulation tissue may be
explained by a secondary e¡ect of highly organized new blood
vessels on the supply of nutrients and oxygen to the cells,
rather than a direct e¡ect of HGF/SF.
Recent studies using a rabbit model of hindlimb ischemia
showed that administration of recombinant human HGF/SF
was associated with a signi¢cant improvement in collateral
formation and regional blood £ow, and a signi¢cant reduction
in muscle atrophy [23]. Overexpression of HGF/SF in our
study induced rapid formation of highly vascularized granu-
lation tissue, in which increased cell proliferation and mark-
edly thicker collagen deposition were noted. These results im-
ply a therapeutic utility for HGF/SF administration on skin
wound sites such as deep burns or refractory skin ulcers as-
sociated with various diseases. However, we previously dem-
onstrated that chronic exposure to high levels of HGF/SF
caused several adverse e¡ects such as renal dysfunction, in-
testinal disorders and, ultimately, neoplasia at multiple sites
[27,46^48]. Therefore, when applied as a clinical reagent, short
Fig. 5. Immunohistological analysis of HGF/SF and VEGF during wound healing. Sections of day 14 wounds were stained with an anti-HGF/
SF (A and B) and anti-VEGF antibody (C and D). Intense HGF/SF and VEGF staining were detected in the endothelial cells and ¢broblasts
in granulation tissue in HGF/SF transgenic mice (B) and (D) relative to their non-transgenic littermates (A) and (C). Original magni¢cation:
U500.
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term and/or local, rather than systemic, administration of
HGF/SF would be desirable for treating wounds. For exam-
ple, HGF/SF could be applied topically over the wound site,
or injected locally at the wound edge.
In summary, we have demonstrated here that neovasculari-
zation and granulation tissue formation are accelerated under
conditions of overexpression of HGF/SF. Our results suggest
that HGF/SF has a signi¢cant e¡ect on organization and
vascularization of granulation tissue during wound healing
in vivo, involving the induction of VEGF.
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